China Brain-Computer Interface 2025: Neuralink Competitors & Medical Applications
China's brain-computer interface (BCI) industry has emerged as a major competitor to Neuralink, with multiple companies advancing both invasive and non-invasive technologies. NeuraMatrix in Shanghai developed a 65,536-channel neural chip with the highest electrode count globally. BrainCo achieved commercial success with non-invasive BCI headbands for focus monitoring and prosthetic control. Tsinghua University conducted China's first human trial of a wireless invasive BCI implant in 2024, enabling a paralyzed patient to control a robotic arm. China's BCI market reached 3 billion RMB in 2025, with medical rehabilitation, neural disease treatment, and brain-health monitoring as primary applications.
TL;DR
China BCI market reached 3B RMB. NeuraMatrix developed 65,536-channel neural chip (highest globally). Tsinghua conducted first human wireless BCI implant trial. BrainCo sells non-invasive BCI commercially. Medical rehabilitation is the primary application.
Key Insights
NeuraMatrix Neural Chip
NeuraMatrix, a Shanghai-based startup, developed a neural recording chip with 65,536 channels, exceeding Neuralink's 1,024 channels. The chip supports both recording and stimulation with ultra-low power consumption. Animal trials demonstrated high-fidelity brain signal recording for motor cortex decoding. The company raised 1 billion RMB in Series B funding.
Tsinghua Human Trial
Tsinghua University conducted China's first human trial of a wireless invasive BCI implant in late 2024. A paralyzed patient received a 256-electrode implant enabling control of a robotic arm for drinking, eating, and typing. The wireless system transmits neural data at 1Mbps with sub-millisecond latency. Three additional patients enrolled in 2025.
BrainCo Commercial BCI
BrainCo sold over 100,000 non-invasive BCI headbands globally, primarily for focus monitoring in education and prosthetic control. The company's FocusCalm headband achieved FDA clearance for ADHD monitoring. BrainCo's prosthetic hand, controlled by EEG signals, costs under $5,000, compared to $50,000+ for myoelectric prosthetics.
Medical Applications
Medical applications account for 60% of China's BCI market, including stroke rehabilitation, epilepsy seizure prediction, depression treatment through neural stimulation, and locked-in syndrome communication. Chinese hospitals conducted 500+ BCI-assisted rehabilitation sessions in 2025. Neural stimulation BCI devices showed 70% improvement in chronic stroke patients.
Side-by-Side Comparison
| BCI Company/Project | Technology | Channels | Status | Application |
|---|---|---|---|---|
| NeuraMatrix | Invasive chip | 65,536 | Animal trials | Research, medical |
| Tsinghua University | Invasive wireless | 256 | Human trials (4 patients) | Paralysis rehabilitation |
| BrainCo | Non-invasive EEG | 4-16 | Commercial | Focus, prosthetics |
| NeuroXess | Invasive flexible electrode | 1,024 | Animal trials | Medical |
| Suzhou BioRay | Invasive Utah array | 100 | Human trials | Epilepsy treatment |
| Zhejiang University | Invasive ECoG | 64-256 | Human trials | Stroke rehab |
| Mindrank AI | Neural decoding AI | Software | Pre-clinical | Neural data analysis |
| Tianqiao Chen (InMind) | Invasive + VR | TBD | R&D stage | Brain disease treatment |
Frequently Asked Questions
China's BCI technology shows both competitive advantages and gaps compared to Neuralink: in electrode density, NeuraMatrix's 65,536-channel chip significantly exceeds Neuralink's 1,024-channel N1 chip, though channel count alone does not determine clinical efficacy; in surgical robotics, Neuralink's implantation robot for minimally invasive surgery has no direct Chinese equivalent, with Chinese trials using traditional neurosurgical methods; in human trials, Neuralink has implanted devices in approximately 10 patients (as of early 2025), while China has approximately 4-6 patients across multiple institutions; in non-invasive BCI, China leads with BrainCo's commercial products (100K+ devices sold), while Neuralink focuses exclusively on invasive implants; in regulatory environment, China's NMPA has not yet established a formal pathway for commercial BCI implant approval, while the FDA granted Neuralink Breakthrough Device designation; and in funding, Chinese BCI companies raised approximately 5 billion RMB cumulatively, compared to Neuralink's estimated $600M+ in total funding. China's strengths are in neural chip design, non-invasive applications, and medical rehabilitation, while Neuralink leads in surgical robotics, human trial scale, and regulatory progress.